Köhler B, Achermann J C
Department of Pediatric Endocrinology, University Children's Hospital, Charité, Humboldt University, Augustenburger Platz 1, Berlin, Germany.
Minerva Endocrinol. 2010 Jun;35(2):73-86.
Steroidogenic factor 1 (SF1, NR5A1, Ad4BP) is a nuclear receptor and regulator of multiple genes involved in adrenal and gonadal development, steroidogenesis, and the reproductive axis. Complete deletion of Nr5a1 in XY mice results in adrenal and gonadal agenesis, female external genitalia and presence of Müllerian structures. These findings were first reported in the early 1990s. Subsequently, NR5A1 mutations were found in two 46,XY phenotypic females with Müllerian structures and adrenal failure and in one 46,XX female with adrenal failure. More recently, heterozygous NR5A1 mutations have been identified in a substantial proportion of patients with 46,XY disorders of sex development (46,XY DSD) without adrenal insufficiency. Most of these individuals display severe underandrogenization with ambiguous genitalia at birth, partial gonadal dysgenesis, and absence of Müllerian structures or remnants. Some of the patients have a milder phenotype such as hypospadias and cryptorchidism, due to less severe defects in androgen synthesis. Testosterone, inhibin B and AMH are usually low indicating a partial (or sometimes progressive) form of gonadal dysgenesis in most cases. However, normal testosterone production at birth might also be present. The frequency of NR5A1 mutations in otherwise unexplained 46,XY DSD with underandrogenization and partial testicular dysgenesis has been estimated to be about 15%. Furthermore, NR5A1 mutations have now been found in women with familial and sporadic 46,XX primary ovarian insufficiency without adrenal failure. These human phenotypes associated with NR5A1 mutations show that SF-1 is a key factor involved in both human testis and ovarian development, but that human adrenal development seems to be more resistant to the effects of SF-1 haploinsufficiency than gonadal development. Patients with 46,XY DSD and mild underandrogenization due to partial testicular dysgenesis should possibly be assigned to the male sex, as small testes with Leydig, Sertoli and germ cells are present in almost all cases. Additionally, spontaneous virilization in puberty might be possible in patients with NR5A1 mutations. However, fertility options and the risk of testicular malignancy and adrenal insufficiency in adulthood are unknown and need to be investigated in long-term outcome studies.
类固醇生成因子1(SF1,NR5A1,Ad4BP)是一种核受体,可调节参与肾上腺和性腺发育、类固醇生成及生殖轴的多个基因。XY小鼠中Nr5a1的完全缺失会导致肾上腺和性腺发育不全、女性外生殖器以及苗勒氏结构的存在。这些发现最早在20世纪90年代初被报道。随后,在两名具有苗勒氏结构和肾上腺功能衰竭的46,XY表型女性以及一名患有肾上腺功能衰竭的46,XX女性中发现了NR5A1突变。最近,在相当一部分无肾上腺功能不全的46,XY性发育障碍(46,XY DSD)患者中鉴定出了杂合性NR5A1突变。这些个体中的大多数在出生时表现出严重的雄激素不足,伴有生殖器模糊、部分性腺发育不全以及苗勒氏结构或残余物的缺失。一些患者具有较轻的表型,如尿道下裂和隐睾症,这是由于雄激素合成缺陷不太严重所致。睾酮、抑制素B和抗苗勒氏激素通常较低,这表明在大多数情况下存在部分(或有时是进行性)性腺发育不全的形式。然而,出生时也可能出现正常的睾酮分泌。在其他原因不明的伴有雄激素不足和部分睾丸发育不全的46,XY DSD中,NR5A1突变的频率估计约为15%。此外,现在在患有家族性和散发性46,XX原发性卵巢功能不全且无肾上腺功能衰竭的女性中也发现了NR5A1突变。这些与NR5A1突变相关的人类表型表明,SF-1是参与人类睾丸和卵巢发育的关键因素,但人类肾上腺发育似乎比性腺发育对SF-1单倍体不足的影响更具抗性。由于部分睾丸发育不全导致46,XY DSD且雄激素不足较轻的患者可能应被判定为男性,因为几乎所有病例中都存在带有Leydig细胞、支持细胞和生殖细胞的小睾丸。此外,携带NR5A1突变的患者在青春期可能会出现自发男性化。然而,生育选择以及成年后患睾丸恶性肿瘤和肾上腺功能不全的风险尚不清楚,需要在长期结局研究中进行调查。